1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6945655E5CF760D7465257F1B0042ED62
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-role-medical-affairs-oncology-launch-excellence
18
19
20107.23.129.77
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

Best Practices and the Role of Medical Affairs in Oncology Launch Excellence

ID: 5389


Features:

14 Info Graphics

12 Data Graphics

100+ Metrics

6 Narratives


Pages/Slides: 36


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Best Practices and the Role of Medical Affairs in Oncology Launch Excellence”

STUDY OVERVIEW

Regulatory reforms in the healthcare industry have transformed the role of the Medical Affairs function. It has evolved beyond its traditional support role into a more prominent oncology launch role that extends from the pre-launch phase to well beyond market entry.

As an interface between biopharmaceutical companies and external stakeholders, the Medical Affairs group plays a critical role in the successful launch of oncology products. Best Practices, LLC conducted this study to provide benchmarks on how Medical Affairs' leaders with oncology companies approach launch activities around thought leaders, MSLs, and launch investment. The study provides best practices and winning strategies in oncology launch excellence from Medical Affairs leaders at leading biopharmaceutical companies.

KEY TOPICS

Medical Affairs' Role in Launch Activities
Thought Leader Tiering
Thought Leader Targeting and MSL Coverage
Launch Investment
Medical Affairs Investment Allocation

SAMPLE KEY METRICS

Timing of Strategies Used for Thought Leader (TL) Tiering
Number of Thought Leaders Targeted During Pre-Launch and Post-Launch
Number of Medical Science Liaisons (MSLs) Employed During Pre-Launch and Post-Launch
Number of TLs Targeted Per MSLs Employed During Pre-Launch and Post-Launch
Total Launch Investment - Pre-Launch and Post-Launch
Total Medical Affairs Launch Investment - Pre-Launch and Post-Launch
Number of Medical Affairs Launch FTEs per Product - Pre-Launch and Post-Launch
Percentage of Total Medical Affairs Launch Investment Allocated to Different Medical Affairs Activities

SAMPLE KEY FINDING

Medical Affairs’ Role in Launch Activities: Medical Affairs is heavily involved in four launch activities within participating organizations: Scientific Publication, Continuing Medical Education, Real World Data Generation & Analysis, MSL activities.

    Medical Affairs leads TL Activities and plays a key role between companies and decision makers during launch process. This requires companies to create strong MSL teams, acquire the right talent and provide effective training.

    Medical Affairs also plays a critical role in internal education and guiding commercial strategies regarding products. This provides Medical Affairs leaders with the opportunity to convey the needs of key decision makers, thus companies to improve their products.

METHODOLOGY

Best Practices, LLC engaged 11 executives from leading life sciences companies. The study analyzes companies that focus on oncology therapies.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Astellas; Incyte; Bayer; Insys Therapeutics; Insyght; Jazz Pharmaceuticals; Merck; Onyx Pharmaceuticals; ProStrakan; Roche; Sanofi


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.